HCP Live Staff

EP. 1: Schuyler Jones, MD: CAD/PAD: Identifying Risk & Summary of Recent Clinical Trials

EP. 2: Tracy Wang, MD: Extended Thromboprophylaxis: What Do We Know About Scoring, Risk and Contemporary Trials?

EP. 3: Christopher Granger, MD: Atrial Fibrillation: What Have We Learned About NOACs in Special Populations?

EP. 4: Manesh Patel, MD: Putting This All Together: Treatment Pyramid

On June 23, Manesh Patel, MD, Chief of Cardiology and Clinical Pharmacology, Duke University School of Medicine, led the HCPLive® State of the Science Event "Institutional Perspectives in Cardiology: Cardiovascular Risk Management."

Patel was joined by his colleagues at the Duke University School of Medicine, including Schuyler Jones, MD, Tracy Wang, MD, and Christopher Granger, MD, to discuss recent trials, identify risk, and treatment options in the cardiovascular risk management space.  

The conversation surrounded the following topics:

CAD/PAD: Identifying Risk & Summary of Recent Clinical Trials

Extended Thromboprophylaxis: What Do We Know About Scoring, Risk and Contemporary Trials?

Atrial Fibrillation: What Have We Learned About NOACs in Special Populations?

Putting This All Together: Treatment Pyramid

Videos

In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space. 

Institutional Perspectives: Cardiovascular Risk Management, Chaired By Manesh Patel, MD 

Ryan Ungaro, MD: Managing IBD During COVID-19

Jean-Frederic Colombel, MD, PhD: Early Use of Biologics

Bruce Sands, MD: Emerging Therapies: The Return of Small Molecules

A trio of clinicians recently came together to present data and expertise on a variety of issues related to 

On June 10, Bruce E. Sands, MD, Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), led the HCPLive® State of the Science Event called Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease.

Joined by Ryan Ungaro, MD, Assistant Professor of Medicine in the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai and Jean-Frederic Colombel, MD, Director Inflammatory Bowel Disease Center Icahn School of Medicine at Mount Sinai, the trio discussed the following topics:

Emerging Therapies: Newer Biologic Therapies

Emerging Therapies: The Return of Small Molecules

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

IPG: Inflammatory Bowel Disease Chaired by Bruce Sands, MD

Tanzeum (albiglutide) injection has been approved by the US Food and Drug Administration to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.

The once-weekly subcutaneous injection was 

 after being evaluated in 8 studies that involved more than 5,000 patients with type 2 diabetes, more than 2,000 of whom were treated with Tanzeum. According to a 

 from GlaxoSmithKline, the studies “evaluated albiglutide against commonly-used classes of type 2 diabetes treatment… in patients at different stages of the disease, as well as those with renal impairment.” In the trials, patients showed improvement in their hemoglobin A1c (HbA1c) level.

Tanzeum is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is a hormone that assists in the normalizing of blood sugar levels. It can be used as a standalone treatment or in combination with other type 2 diabetes medications, including metformin, glimepiride, pioglitazone, and insulin.

“Many type 2 diabetes patients struggle to keep their blood sugar within the recommended levels,” Vlad Hogenhuis, Senior Vice-President and Head, GSK Global Cardiovascular, Metabolic and Neurosciences Franchise, said in a press release. “We are pleased that the approval of Tanzeum provides an effective new weekly GLP-1 treatment option for appropriate patients in the US.”

Tanzeum is not recommended for patients with type 1 diabetes, increased ketones, or as first-line therapy for patients who can’t be managed with diet and exercise. Side effects noted from the phase 3 trials include diarrhea, nausea, and injection site reactions.

Tanzeum will include a boxed warning on its label stating that “tumors of the thyroid gland (thyroid C-cell tumors) have been observed in rodent studies with some GLP-1 receptor agonists, but that it is unknown whether Tanzeum causes thyroid C-cell tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC), in humans,” according to the FDA announcement.

The FDA will require several postmarketing studies as a condition of approval, including a trial to evaluate safety and efficacy in children, an MTC case registry of at least 15 years, and a trial to evaluate the cardiovascular risk of Tanzeum in patients with high baseline risk of cardiovascular disease.

Tanzeum was approved with a Risk Evaluation and Mitigation Strategy (REMS), which “consists of a communication plan to inform health care providers about the serious risks associated with Tanzeum.”

Articles

The US Food and Drug Administration has approved Tanzeum (albiglutide), a once-weekly subcutaneous injection for the treatment of type 2 diabetes in adults.